Biological response modifiers for the treatment of Crohn’s disease

Bibliography

• FOLWACZNY C, GLAS J, TOROK HP: Crohn's disease: an immunodeficiency? Gastroenterol Hepatol (2003) 15(6):621–626.
   Google Scholar
• PODOLSKY DK: Inflammatory bowel disease. N Engl. J. Med. (2002) 347(6):417–429.
   PubMed Web of Science ®Google Scholar
• EGAN LJ, SANDBORN WJ: Advances in the treatment of Crohn's disease. Gastroenterology (2004) 126(6):1574–1581.
   PubMed Web of Science ®Google Scholar
• AHMAD T, TAMBOLI CP, JEWELL D, COLOMBELJF: Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology (2004) 126(6):1533–1549.
   PubMed Web of Science ®Google Scholar
• REIMUND JM, WITTERSHEIM C,DUMONT S et al: Increased production of tumour necrosis factor-alpha interleulkin-1 beta, and interleulkin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut (1996) 39(5):684–689.
   PubMed Web of Science ®Google Scholar
• REIMUND JM, WITTERSHEIM C, DUMONT S et al.: Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. Clin. Immunol (1996) 16(3):144–150.
   Web of Science ®Google Scholar
• REINECKER HC, STEFFEN M, WITTHOEFT T et al.: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol (1993) 94(1):174–181.
   PubMed Web of Science ®Google Scholar
• STROBER W, LUDVIKSSON BR, FUSS IJ: The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease. Ann. Intern. Med. (1998) 128(10):848–856.
   PubMed Web of Science ®Google Scholar
• NEURATH ME FUSS I, PASPARAKIS M et al.: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. j Immunol (1997) 27(7):1743–1750.
   Google Scholar
• TARGAN SR, HANAUER SB,VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl. I Med. (1997) 337(15):1029–1035.
   Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN S et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl. Med. (1999) 340(18):1398–1405.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, VAN ASSCHE G, VERMEIRE S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology (2004) 126(6):1593–1610.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124(7):1774–1785.
   PubMed Web of Science ®Google Scholar
• D'HAENS G, SWIJSEN C, NOMAN M et al.: Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am. Gastroenterol (2001) 96(9):2564–2568.
   Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121(5):1088–1094.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, LEMMENS L,VAN ASSCHE G et al: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment. Pharmacol Ther. (2003) 17(2):185–192.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. (1999) 5(2):119–133.
   PubMed Web of Science ®Google Scholar
• STACK WA, MANN SD, ROY AJ et al.:Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet (1997) 349(9051):521–524.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, FEAGAN BG, HANAUER SB et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 120(6):1330–1338.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, SANDBORN WJ, BAKER J: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid dependent Crohn's disease. Gastroenterology (2000) 118:A655.
   PubMedGoogle Scholar
• SANDBORN W, FEAGAN B, RADFORD-SMITH GL: Randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-a, in patients with moderate to severe Crohn's disease. Gastroenterology (2003) 124:A61.
   Web of Science ®Google Scholar
• HANAUER S, PRESENT D,TARGAN SR: CDP571, a humanized monoclonal antibody to TNF-a, is well tolerated in Crohn's disease patients with previous hypersensitivity to infliximab. Gastroenterology (2003) 124:A517.
   Web of Science ®Google Scholar
• SCHREIBER S, RUTGEERTS P, FEDORAK R: CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). The CDP870 Crohn's Disease Study Group. Gastroenterology (2003) 124:A61.
   Google Scholar
• WINTER T, WRIGHT J, GHOSH S: Intravenous CDP870, a humanised anti-TNF antibody fragment, in patients with active Crohn's disease-an exploratory study. Gastroenterology (2003) 124:A377.
   PubMed Web of Science ®Google Scholar
• HANAUER S, LUKAS M,MACINTOSH D et al.: A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology (2004) 127(1):332.
   Google Scholar
• HOMMES D, VAN DEN BLINK B, PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology (2002) 122(1):7–14.
   Google Scholar
• PARRONCHI P, ROMAGNANI P, ANNUNZIATO F et al.: Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. Pathol. (1997) 150(3):823–832.
   PubMed Web of Science ®Google Scholar
• MAERTEN P, SHEN C, COLPAERT S et al.: Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin. Exp. Immunol (2004) 135(2):310–317.
   PubMed Web of Science ®Google Scholar
• PIZARRO TT, MICHIE MH, BENTZ M et al: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. Immunol (1999) 162(11):6829–6835.
   Web of Science ®Google Scholar
• CAMOGLIO L, TE VELDE AA, TIGGES AJ, DAS PK,VAN DEVENTER SJ: Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm. Bowel Dis. (1998) 4(4):285–290.
   PubMed Web of Science ®Google Scholar
• ITO H, HIROTANI T, YAMAMOTO M, OGAWA H, KISHIMOTO T: Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. Gastroenterol (2002) 37\(Suppl. 14):56–61.
   Google Scholar
• ITO H, TAKAZOE M, FUKUDA Y et al:A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 126(4):989–996; discussion 947.
   Google Scholar
• FUSS IJ, MARTH T, NEURATH MF et al.: Anti-interleukin 12 treatment regulates apoptosis of Thl T cells in experimental colitis in mice. Gastroenterology (1999) 117(5):1078–1088.
   PubMed Web of Science ®Google Scholar
• DUCHMANN R,SCHMITT E, KNOLLE P,MEYER ZUM BUSCHENFELDE KH, NEURATH M: Tolerance towards residentintestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Ear: Immunol (1996) 26(4):934–938.
   PubMed Web of Science ®Google Scholar
• WIRTZ S, BECKER C, BLUMBERG R, GALLE PR, NEURATH MF: Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. I Immunol (2002) 168(1):411–420.
   PubMed Web of Science ®Google Scholar
• HIBI T, INOUE N, OGATA H, NAGANUMA M: Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. Gastroenterol (2003) 38\(Suppl. 15):36–42.
   Google Scholar
• MANNON P, FUSS I, STROBER W: Anti-interleukin-12 treats active Crohn's disease. Gastroenterology (2004) 126:A22–A23.
   Web of Science ®Google Scholar
• POWRIE F, LEACH MW, MAUZE S et al: Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity (1994) 1(7):553–562.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, REINISCH W, COLOMBEL JF et al.: Preliminary results of a Phase I/II study of Huzaf, an anti-IFN-gamma monoclonal antibody, in patients with moderate to severe active Crohn's disease. Gastroenterology (2002) 122:A61.
   Web of Science ®Google Scholar
• HOMMES D, MIKHAJLOVA T, STOINOV S et al.: Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gastroenterology (2004) 127(1):332.
   Web of Science ®Google Scholar
• LI MC, HE SH: IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol (2004) 10(5):620–625.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119(6):1461–1472.
   Google Scholar
• STEIDLER L, HANS W, SCHOTTE L et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289(5483):1352–1355.
   PubMed Web of Science ®Google Scholar
• SCHWERTSCHLAG US,TREPICCHIO WL, DYKSTRA KH et al.: Hematopoietic, immunomodulatory andepithelial effects of interleukin-11.Leukemia (1999) 13(9):1307–1315.
   Google Scholar
• KEITH JC JR, ALBERT L, SONIS ST, PFEIFFER CJ, SCHAUB RG: IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (1994) 12\(Suppl. 1):79–89; discussion 89–90.
   Google Scholar
• QIU BS, PFEIFFER CJ, KEITH JC JR: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig. Dis. ScL (1996) 41(8):1625–1630.
   PubMed Web of Science ®Google Scholar
• SANDS BE, BANKS, SNINSKY CA et al: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 117(1):58–64.
   PubMed Web of Science ®Google Scholar
• SANDS BE, WINSTON BD, SALZBERG B et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment. Pharmacol The]: (2002) 16(3):399–406.
   PubMed Web of Science ®Google Scholar
• GASCHE C, REINISCH W, VOGELSANG H et al.: Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. DV. Dis. Se/. (1995) 40(4):800–804.
   PubMed Web of Science ®Google Scholar
• STUBER E, STROBER W,NEURATH M: Blocking the CD4OL-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. I Exp. Med. (1996) 183(2):693–698.
   PubMed Web of Science ®Google Scholar
• PODOLSKY DK, LOBB R, KING N et al.: Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. Clin. Invest. (1993) 92(1):372–380.
   Google Scholar
• HESTERBERG PE, WINSOR-HINES D, BRISKIN MJ et al.: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta?. Gastroenterology (1996) 111(5):i373–i380.
   Google Scholar
• GORDON FH, LAI CW,HAMILTON MI et al: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology (2001) 121(2):268–274.
   PubMed Web of Science ®Google Scholar
• GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab for active Crohn's disease. N Engl. Med. (2003) 348(1):24–32.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, COLOMBEL J, ENNS Ret al: Subanalyses from a Phase III study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). Gut (2003) 52(Suppl. VI):A239.
   Google Scholar
• SANDBORN W, COLOMBEL JF, ENNS R et al.: A Phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2). Gastroenterology (2004) 127(1):332.
   Web of Science ®Google Scholar
• FEAGAN BG, GREENBERG G, WILD G: Efficacy and safety of a humanized alpha4 beta7 antibody in active Crohn's disease. Gastroenterology (2003) 124:A25.
   Web of Science ®Google Scholar
• SCHREIBER S, NIKOLAUS S, MALCHOW H et al.: Absence of efficacy of subcutaneous antisense I CAM-1 treatment of chronic active Crohn's disease. Gastroenterology (2001) 120(6):1339–1346.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, CHEY WY, GOFF J et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut (2002) 51(1):30–36.
   PubMed Web of Science ®Google Scholar
• SLONIM AE, BULONE L,DAM ORE MB et al.: A preliminary study of growth hormone therapy for Crohn's disease. N Engl. Med. (2000) 342(22):1633–1637.
   Google Scholar
• DIECKGRAEFE BK, KORZENIK JR: Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet (2002) 360(9344):1478–1480.
   PubMed Web of Science ®Google Scholar
• KORZENIK J, STONE C,VALENTINE J, HAUSMAN D: Safety of repeated cycles of sagramostim in patients with moderately-to-severely active Crohn's disease (CD): experience from an open label extension trial. Gastroenterology (2003) 124:A626.
   PubMedGoogle Scholar
• ANDUS T, KLEBL F, ROGLER G et al.:Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment. Pharmacol The]: (2003) 17(3):409–414.
   PubMed Web of Science ®Google Scholar
• SUMMERS RW, ELLIOTT DE, QADIR K et al.: Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am. Gastroenterol (2003) 98(9):2034–2041.
   PubMed Web of Science ®Google Scholar
• SUMMERS RW, ELLIOTT DE, THOMPSON R, URBAN JF JR, WEINSTOCK JV: Trial of helminth ova in active Crohn's disease. Gastroenterology (2004) 126:A75.
   Web of Science ®Google Scholar
• SARTOR RB: Therapeutic manipulation ofthe enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology (2004) 126(6):1620–1633.
   PubMed Web of Science ®Google Scholar